RUET , A.

Background: Despite a second-line treatment with fingolimod (FNG), some patients with relapsing-remitting Multiple Sclerosis (RR-MS) may have residual disease activity. The current therapeutic strategy is based on the switch to either natalizumab (NTZ) or anti-CD20 (rituximab or ocrelizumab). To date the relative effectiveness of these two...

Introduction: In relapsing-remitting multiple sclerosis (RRMS), the early identification of suboptimal responders would prevent irreversible disability progression.Objectives: We aimed to develop and validate a dynamic scoring system to help in the early decision of switch from first to second-line therapy.Methods: From a French cohort of...

Objectives: Establish recommendations for the management of UTIs in MS patients.Background: Urinary tract infections (UTIs) are common during multiple sclerosis (MS) and are one of the most common comorbidities potentially responsible for deaths from urinary sepsis.Methods: The recommendations attempt to answer three main questions about UTIs...